Testing a drug called roscovitine in a mouse model of Huntington's disease
In vivo efficacy of a kinase inhibitor, roscovitine, in HD mouse model
['FUNDING_R21'] · JOHNS HOPKINS UNIVERSITY · NIH-10586210
This study is looking at how well a drug called roscovitine can help protect against the harmful effects of the faulty protein that causes Huntington's disease, using mice to see if it could lead to new treatments for people with this condition.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10586210 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of roscovitine, a kinase inhibitor, in treating Huntington's disease by targeting the mutant huntingtin protein that causes neurodegeneration. The study uses a mouse model to assess how well roscovitine can protect against the toxicity of this protein. By focusing on specific phosphorylation sites on the mutant protein, the research aims to provide insights into potential therapeutic strategies that could modify the disease's progression. If successful, this could lead to new treatment options for patients suffering from Huntington's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington's disease or those at risk due to family history.
Not a fit: Patients with other neurodegenerative diseases unrelated to Huntington's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic approach for Huntington's disease, potentially slowing or modifying its progression.
How similar studies have performed: Previous studies have shown promise with similar kinase inhibitors in other models, but this specific approach in Huntington's disease is novel.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JIN, JING — JOHNS HOPKINS UNIVERSITY
- Study coordinator: JIN, JING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Huntington Disease, Huntington's Disease, Huntington's Disease Pathway